Butterfly Network, Inc. - Quarter Report: 2021 September (Form 10-Q)

September 30,

December 31,

Due from related parties

Due to related parties

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39292

Butterfly Network, Inc.

(Exact name of registrant as specified in its charter)


Delaware		84-4618156
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

530 Old Whitfield Street Guilford, Connecticut		06437
(Address of principal executive offices)		(Zip Code)

(203) 689-5650

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, $0.0001 Par Value Per Share	BFLY	The New York Stock Exchange
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share	BFLY WS	The New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	¨	Accelerated filer	¨

Non-accelerated filer	☒	Smaller reporting company	☒	Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 1, 2021, the registrant had 170,830,161 shares of Class A common stock outstanding and 26,426,937 shares of Class B common stock outstanding.

Table of Contents

TABLE OF CONTENTS

		Page

	Cautionary Statement Regarding Forward-Looking Statements	2

Part I	Financial Information	3

Item 1.	Financial Statements	3

	Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020 (Unaudited)	3

	Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2021 and 2020 (Unaudited)	4

	Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the three and nine months ended September 30, 2021 and 2020 (Unaudited)	5

	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2021 and 2020 (Unaudited)	6

	Notes to Condensed Consolidated Financial Statements (Unaudited)	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	39

Item 4.	Controls and Procedures	39

Part II	Other Information	39

Item 1.	Legal Proceedings	41

Item 1A.	Risk Factors	41

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	41

Item 3.	Defaults Upon Senior Securities	41

Item 4.	Mine Safety Disclosures	41

Item 5.	Other Information	41

Item 6.	Exhibits	41

Signatures		44

In this Quarterly Report on Form 10-Q, the terms “we,” “us,” “our,” the “Company” and “Butterfly” mean Butterfly Network, Inc. (formerly Longview Acquisition Corp.) and our subsidiaries. On February 12, 2021 (the “Closing Date”), Longview Acquisition Corp., a Delaware corporation (“Longview” and after the Business Combination described herein, the “Company”), consummated a business combination (the “Business Combination”) pursuant to the terms of the Business Combination Agreement, dated as of November 19, 2020 (the “Business Combination Agreement”), by and among Longview, Clay Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Butterfly Network, Inc., a Delaware corporation (“Legacy Butterfly”). Immediately upon the consummation of the Business Combination and the other transactions contemplated by the Business Combination Agreement (collectively, the “Transactions”, and such completion, the “Closing”), Merger Sub merged with and into Legacy Butterfly, with Legacy Butterfly surviving the Business Combination as a wholly-owned subsidiary of Longview (the “Merger”). In connection with the Transactions, Longview changed its name to “Butterfly Network, Inc.” and Legacy Butterfly changed its name to “BFLY Operations, Inc.”

Table of Contents

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that relate to future events or our future financial performance regarding, among other things, the plans, strategies and prospects, both business and financial, of the Company. These statements are based on the beliefs and assumptions of the Company’s management team. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

●

the success, cost and timing of our product development activities;

●

the potential attributes and benefits of our products and services;

●

our ability to obtain and maintain regulatory approval for our products, and any related restrictions and limitations of any authorized product;

●

our ability to identify, in-license or acquire additional technology;

●

our ability to maintain our existing license, manufacturing and supply agreements;

●

our ability to compete with other companies currently marketing or engaged in the development of ultrasound imaging devices, many of which have greater financial and marketing resources than us;

●

the size and growth potential of the markets for our products and services, and the ability of each to serve those markets, either alone or in partnership with others;

●

our estimates regarding expenses, revenue, capital requirements and needs for additional financing;

●

our ability to raise financing in the future;

●

our financial performance; or

●

the potential impacts of the COVID-19 pandemic on our business operations or financial condition.

These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates” or “intends” or similar expressions or phrases, or the negative of those expressions or phrases. The forward-looking statements are based on projections prepared by, and are the responsibility of, the Company’s management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions relating, among other things, to:

●

our rapid growth may not be sustainable and depends on our ability to attract and retain customers;

●

our business could be harmed if we fail to manage our growth effectively;

●

the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition and our ability to grow and manage growth profitably and retain our key employees;

●

our projections are subject to risks, assumptions, estimates and uncertainties;

●

our business is subject to a variety of U.S. and foreign laws, which are subject to change and could adversely affect our business;

●

the pricing of our products and services and reimbursement for medical procedures conducted using our products and services;

●

changes in applicable laws or regulations;

●

our ability to remediate the material weakness in our internal controls over financial reporting;

●

failure to protect or enforce our intellectual property rights could harm our business, results of operations and financial condition;

●

the ability to maintain the listing of our Class A common stock on the New York Stock Exchange;

●

economic downturns and political and market conditions beyond our control could adversely affect our business, financial condition and results of operations; and

●

the impact of the COVID-19 pandemic on our business.

These and other risks and uncertainties are described in greater detail under the caption “Risk Factors” in Item 1A of Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as amended, in Item 1A of Part II of this quarterly report, and in other filings that we make with the Securities and Exchange Commission, or SEC. The risks described under the heading “Risk Factors” are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can the Company assess the impact of all such risk factors on its business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. The Company undertakes no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

BUTTERFLY NETWORK, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)


	September 30,		December 31,
	2021		2020
Assets
Current assets:
Cash and cash equivalents	$	153,326	$	60,206
Marketable securities		315,099		—
Accounts receivable, net		9,538		5,752
Inventories		23,820		25,805
Current portion of vendor advances		24,975		2,571
Prepaid expenses and other current assets		16,753		2,998
Total current assets	$	543,511	$	97,332
Property and equipment, net		9,368		6,870
Non-current portion of vendor advances		20,601		37,390
Other non-current assets		6,838		5,599
Total assets	$	580,318	$	147,191
Liabilities, convertible preferred stock and stockholders’ equity (deficit)
Current liabilities:
Accounts payable	$	5,017	$	16,400
Deferred revenue, current		12,015		8,443
Accrued purchase commitments, current		5,329		22,890
Accrued expenses and other current liabilities		22,809		21,962
Total current liabilities	$	45,170	$	69,695
Deferred revenue, non-current		4,878		2,790
Convertible debt		—		49,528
Loan payable		—		4,366
Warrant liabilities		56,796		—
Accrued purchase commitments, non-current		14,200		19,660
Other non-current liabilities		8,013		2,146
Total liabilities	$	129,057	$	148,185
Commitments and contingencies (Note 16)
Convertible preferred stock:
Convertible preferred stock (Series A, B, C and D) $.0001 par value with an aggregate liquidation preference of $0 and $383,829 at September 30, 2021 and December 31, 2020, respectively; 0 and 107,197,118 shares authorized, issued and outstanding at September 30, 2021 and December 31, 2020, respectively		—		360,937
Stockholders’ equity (deficit):
Class A common stock $.0001 par value; 600,000,000 and 116,289,600 shares authorized at September 30, 2021 and December 31, 2020, respectively; 170,573,310 and 6,593,291 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively		17		1
Class B common stock $.0001 par value; 27,000,000 and 26,946,089 shares authorized at September 30, 2021 and December 31, 2020, respectively; 26,426,937 and 0 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively		3		—
Additional paid-in capital		863,240		32,874
Accumulated deficit		(411,999)		(394,806)
Total stockholders’ equity (deficit)	$	451,261	$	(361,931)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$	580,318	$	147,191

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

BUTTERFLY NETWORK, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)


	Three months ended September 30,				Nine months ended September 30,
	2021		2020		2021		2020
Revenue:
Product	$	10,848	$	8,621	$	33,455	$	25,820
Subscription		3,773		1,514		10,123		4,777
Total revenue	$	14,621	$	10,135	$	43,578	$	30,597
Cost of revenue:
Loss on product purchase commitments		11,623		63,993		11,623		63,993
Product		7,584		14,619		21,090		35,266
Subscription		536		774		1,351		1,260
Total cost of revenue	$	19,743	$	79,386	$	34,064	$	100,519
Gross profit	$	(5,122)	$	(69,251)	$	9,514	$	(69,922)
Operating expenses:
Research and development	$	21,654	$	11,971		54,459		36,427
Sales and marketing		14,203		5,538		34,550		17,408
General and administrative		16,008		5,068		67,928		15,651
Total operating expenses		51,865		22,577		156,937		69,486
Loss from operations	$	(56,987)	$	(91,828)	$	(147,423)	$	(139,408)
Interest income	$	893	$	16		1,739		238
Interest expense		—		(300)		(645)		(418)
Change in fair value of warrant liabilities		42,958		—		130,528		—
Other income (expense), net		(428)		(84)		(1,320)		(183)
Loss before provision for income taxes	$	(13,564)	$	(92,196)	$	(17,121)	$	(139,771)
Provision for income taxes		(3)		12		72		32
Net loss and comprehensive loss	$	(13,561)	$	(92,208)	$	(17,193)	$	(139,803)
Net loss per common share attributable to Class A and B common stockholders, basic and diluted	$	(0.07)	$	(15.20)	$	(0.10)	$	(23.20)
Weighted-average shares used to compute net loss per share attributable to Class A and B common stockholders, basic and diluted		196,095,192		6,066,117		165,656,408		6,026,658

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

BUTTERFLY NETWORK, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(In thousands, except share amounts)

(Unaudited)


Three months ended September 30, 2020

	Convertible			Class A			Class B
	Preferred			Common			Common			Additional				Total
	Stock			Stock			Stock			Paid-In		Accumulated		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Equity (Deficit)
June 30, 2020	107,197,118	$	360,937	6,045,858	$	1	—	$	—	$	25,393	$	(279,656)	$	(254,262)
Net loss	—		—	—		—	—		—		—		(92,208)		(92,208)
Common stock issued upon exercise of stock options	—		—	44,602		—	—		—		167		—		167
Stock-based compensation expense	—		—	—		—	—		—		2,409		—		2,409
September 30, 2020	107,197,118	$	360,937	6,090,460	$	1	—	$	—	$	27,969	$	(371,864)	$	(343,894)

Nine months ended September 30, 2020

	Convertible			Class A			Class B
	Preferred			Common			Common			Additional				Total
	Stock			Stock			Stock			Paid-In		Accumulated		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Equity (Deficit)
December 31, 2019	107,197,118	$	360,937	5,939,950	$	1	—	$	—	$	19,782	$	(232,061)	$	(212,278)
Net loss	—		—	—		—	—		—		—		(139,803)		(139,803)
Common stock issued upon exercise of stock options	—		—	150,510		—	—		—		391		—		391
Stock-based compensation expense	—		—	—		—	—		—		7,796		—		7,796
September 30, 2020	107,197,118	$	360,937	6,090,460	$	1	—	$	—	$	27,969	$	(371,864)	$	(343,894)

Three months ended September 30, 2021

	Convertible			Class A			Class B
	Preferred			Common			Common			Additional				Total
	Stock			Stock			Stock			Paid-In		Accumulated		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Equity (Deficit)
June 30, 2021	—	$	—	167,477,126	$	17	26,426,937	$	3	$	844,770	$	(398,438)	$	446,352
Net loss	—		—	—		—	—		—		—		(13,561)		(13,561)
Common stock issued upon exercise of stock options and warrants	—		—	2,966,397		—	—		—		7,634		—		7,634
Common stock issued upon vesting of restricted stock units	—		—	129,787		—	—		—		—		—		—
Stock-based compensation expense	—		—	—		—	—		—		10,836		—		10,836
September 30, 2021	—	$	—	170,573,310	$	17	26,426,937	$	3	$	863,240	$	(411,999)	$	451,261

Nine months ended September 30, 2021

	Convertible			Class A			Class B
	Preferred			Common			Common			Additional				Total
	Stock			Stock			Stock			Paid-In		Accumulated		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Equity (Deficit)
December 31, 2020	107,197,118	$	360,937	6,593,291	$	1	—	$	—	$	32,874	$	(394,806)	$	(361,931)
Net loss	—		—	—		—	—		—		—		(17,193)		(17,193)
Common stock issued upon exercise of stock options and warrants	—		—	8,268,869		1	—		—		19,322		—		19,323
Common stock issued upon vesting of restricted stock units	—		—	597,021		—	—		—		—		—		—
Conversion of convertible preferred stock	(107,197,118)		(360,937)	80,770,178		8	26,426,937		3		360,926		—		360,937
Conversion of convertible debt	—		—	5,115,140		1	—		—		49,916		—		49,917
Net equity infusion from the Business Combination	—		—	69,228,811		6	—		—		361,281		—		361,287
Stock-based compensation expense	—		—	—		—	—		—		38,921		—		38,921
September 30, 2021	—	$	—	170,573,310	$	17	26,426,937	$	3	$	863,240	$	(411,999)	$	451,261

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

BUTTERFLY NETWORK, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


	Nine months ended September 30,
	2021		2020
Cash flows from operating activities:
Net loss	$	(17,193)	$	(139,803)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,420		904
Non-cash interest expense on convertible debt		389		418
Write-down of inventories		582		6,923
Stock-based compensation expense		38,769		7,727
Change in fair value of warrant liabilities		(130,528)		—
Other		665		731
Changes in operating assets and liabilities:
Accounts receivable		(3,674)		(1,475)
Inventories		1,432		(12,426)
Prepaid expenses and other assets		(8,896)		(340)
Vendor advances		(5,615)		5,003
Accounts payable		(11,276)		3,236
Deferred revenue		5,660		2,662
Accrued purchase commitments		(23,021)		63,376
Accrued expenses and other liabilities		4,876		1,987
Net cash used in operating activities	$	(146,410)	$	(61,077)

Cash flows from investing activities:
Purchases of marketable securities		(1,018,095)		—
Sales of marketable securities		702,152		—
Purchases of property and equipment		(3,826)		(2,597)
Net cash used in investing activities	$	(319,769)	$	(2,597)

Cash flows from financing activities:
Proceeds from exercise of stock options and warrants		19,314		391
Net proceeds from equity infusion from the Business Combination		548,403		—
Proceeds from loan payable		—		4,317
Proceeds from issuance of convertible debt		—		20,650
Payment of loan payable		(4,366)		—
Payments of debt issuance costs		(52)		—
Net cash provided by financing activities	$	563,299	$	25,358
Net (decrease) increase in cash, cash equivalents and restricted cash	$	97,120	$	(38,316)
Cash, cash equivalents and restricted cash, beginning of period		60,206		90,002
Cash, cash equivalents and restricted cash, end of period	$	157,326	$	51,686

Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets
Cash and cash equivalents	$	153,326	$	51,686
Restricted cash		4,000		—
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$	157,326	$	51,686

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

BUTTERFLY NETWORK, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. Organization and Description of Business

Butterfly Network, Inc., formerly known as Longview Acquisition Corp. (the “Company” or “Butterfly”), was incorporated in Delaware on February 4, 2020. The Company’s legal name became Butterfly Network, Inc. following the closing of the business combination discussed in Note 3 “Business Combination”. The prior period financial information represents the financial results and condition of BFLY Operations, Inc.

The Company is an innovative digital health business whose mission is to democratize healthcare by making medical imaging accessible to everyone around the world. Butterfly’s solution uses a unique combination of software and hardware technology to enable medical imaging to drive more clinical insight at patient point-of-care. The hardware platform works alongside cloud-based software that is intended to make the product easy to use, integrate with the clinical workflow and be accessible on a user’s smartphone, tablet and/or healthcare enterprise systems.

The Company operates wholly-owned subsidiaries in Australia, Germany, the Netherlands, the United Kingdom and Taiwan.

Note 2. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of Butterfly Network, Inc. and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company’s audited consolidated financial statements as of and for the years ended December 31, 2020 and 2019. All intercompany balances and transactions are eliminated upon consolidation.

The condensed consolidated balance sheet as of December 31, 2020, included herein, was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including certain notes required by U.S. GAAP, required on an annual reporting basis. Certain prior period amounts have been reclassified to conform to the current period presentation. The Company reclassified the loss on product purchase commitments that was recorded within cost of product revenue on the condensed consolidated statement of operations and comprehensive loss to be presented separately.

In the opinion of management, the accompanying condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods. The results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for any subsequent quarter, the year ending December 31, 2021, or any other period.

Except as described elsewhere in this Note 2, including under the heading “Recent Accounting Pronouncements Adopted”, and Note 3 “Business Combination”, there have been no material changes to the Company’s significant accounting policies as described in the audited consolidated financial statements as of December 31, 2020 and 2019.

COVID-19 Outbreak

The COVID-19 pandemic that began in 2020 has created significant global economic uncertainty and has impacted the Company’s operating results, financial condition and cash flows. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition will depend on

Table of Contents

future developments that are highly uncertain, including those that result from new information that may emerge concerning COVID-19, the actions taken to contain or treat COVID-19 and the economic impacts of COVID-19.

The estimates of the impact on the Company’s business may change based on new information that may emerge concerning COVID-19, the actions to contain it or address its impact and the economic impact on local, regional, national and international markets. The Company has not incurred any significant impairment losses in the carrying values of its assets as a result of the COVID-19 pandemic and is not aware of any specific related event or circumstance that would require the Company to revise the estimates reflected in its condensed consolidated financial statements.

Although the Company has incurred recurring losses in each year since inception, the Company expects its cash and cash equivalents and marketable securities will be sufficient to fund operations for at least the next twelve months

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, marketable securities and accounts receivable. At September 30, 2021, substantially all of the Company’s marketable securities were invested in mutual funds with one financial institution. At September 30, 2021 and December 31, 2020, substantially all of the Company’s cash and cash equivalents were invested in money market accounts at one financial institution. The Company also maintains balances in various operating accounts above federally insured limits. The Company has not experienced significant losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents and marketable securities.

As of September 30, 2021 and December 31, 2020, no customer accounts for more than 10% of the Company’s accounts receivable. For the three and nine months ended September 30, 2021 and 2020, no customer accounts for more than 10% of the total revenues.

Segment Information

The Company’s Chief Operating Decision Maker, its Chief Executive Officer (“CEO”), reviews the financial information presented on a consolidated basis for purposes of allocating resources and evaluating its financial performance. Accordingly, the Company has determined that it operates in a single reportable segment. Substantially all of the Company’s long-lived assets are located in the United States. Since the Company operates in one operating segment, all required financial segment information can be found in the condensed consolidated financial statements.

Use of Estimates

The Company makes estimates and assumptions about future events that affect the amounts reported in its condensed consolidated financial statements and accompanying notes. Future events and their effects cannot be determined with certainty. On an ongoing basis, management evaluates these estimates, judgments and assumptions.

The Company bases its estimates on historical and anticipated results and trends and on various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates, and any such differences may be material to the Company’s condensed consolidated financial statements. Except with respect to estimates related to the warrant liabilities, there have been no material changes to the Company’s use of estimates as described in the audited consolidated financial statements as of December 31, 2020.

Investments in Marketable Securities

The Company’s investments in marketable securities are ownership interests in fixed income mutual funds. The equity securities are stated at fair value, as determined by quoted market prices. As the securities have readily determinable fair value, unrealized gains and losses are reported as other income (expense), net on the condensed consolidated statements of operations and comprehensive loss. Subsequent gains or losses realized upon redemption or sale of these securities are also recorded as other income (expense), net on the condensed consolidated statements of operations and comprehensive loss. The Company considers all of its investments in marketable securities as available for use in current operations and therefore classifies these securities within current assets on the condensed consolidated balance sheets. For the three and

Table of Contents

nine months ended September 30, 2021, the Company recognized $0.2 million and $0.2 million, respectively, of unrealized losses that relate to equity securities still held as of September 30, 2021.

Restricted Cash

Restricted cash includes deposits in financial institutions used to secure a lease agreement. The Company classified the amounts within other non-current assets as the deposits are used to secure a long-term lease. The amount shown as restricted cash is included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the condensed consolidated statement of cash flows.

Warrant Liability

The Company’s outstanding warrants include publicly-traded warrants (the “Public Warrants”) which were issued as one-third of a warrant per unit during the Company’s initial public offering on May 26, 2020 (the “IPO”) and warrants sold in a private placement to Longview’s sponsor (the “Private Warrants”). The Company evaluated its warrants under ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, and concluded that they do not meet the criteria to be classified in stockholders’ equity. Since the Public Warrants and Private Warrants meet the definition of a derivative under ASC 815, the Company recorded these warrants as long-term liabilities on the balance sheet at fair value upon the Closing of the Business Combination, with subsequent changes in their respective fair values recognized in the condensed consolidated statements of operations and comprehensive loss at each reporting date.

Recent Accounting Pronouncements Adopted

In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that Is a Service Contract (Topic 350-40), which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). As a result, eligible implementation costs incurred in a cloud computing arrangement that is a service contract are capitalized as prepaid expenses and other current assets on the balance sheet, recognized on a straight-line basis over its life in the statement of operations and comprehensive loss in the same line item as the fees for the associated arrangement, and the related activity is generally classified as an operating activity in the statement of cash flows. The Company prospectively adopted such guidance on January 1, 2021 and there was no material effect of adoption on the condensed consolidated financial statements as of and for the three and nine months ended September 30, 2021.

Recent Accounting Pronouncements Issued but Not Yet Adopted

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) which outlines a comprehensive lease accounting model and supersedes the prior lease guidance. The new guidance requires lessees to recognize almost all of their leases on the balance sheet by recording a lease liability and corresponding right-of-use assets. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. As per the latest ASU 2020-05 issued by the FASB, entities that have not yet issued or made available for issuance their financial statements as of June 3, 2020 can defer the new guidance for one year. For public entities, this guidance was effective for annual reporting periods beginning January 1, 2019, including interim periods within that annual reporting period. For other entities, this guidance is effective for the annual reporting period beginning January 1, 2022, and interim reporting periods within annual reporting periods beginning January 1, 2023. This will require application of the new accounting guidance at the beginning of the earliest comparative period presented in the year of adoption. The impact of the Company's adoption of Topic 842 to the condensed consolidated financial statements will be to recognize the operating lease commitments as operating lease liabilities and right-of-use assets upon adoption, which will result in an increase in the assets and liabilities recorded on the balance sheet. The Company is continuing its assessment, which may identify additional impacts Topic 842 will have on the condensed consolidated financial statements and disclosures.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires an entity to utilize a new impairment model known as the current expected credit loss (“CECL”) model to estimate its lifetime “expected credit loss” and record an allowance that,

Table of Contents

when deducted from the amortized cost basis of the financial asset, presents the net amount expected to be collected on the financial asset. The CECL model is expected to result in more timely recognition of credit losses. ASU 2016-13 also requires new disclosures for financial assets measured at amortized cost, loans, and available-for-sale debt securities. For public entities, this guidance was effective for annual reporting periods beginning January 1, 2020, including interim periods within that annual reporting period. For other entities, this guidance is effective for the annual reporting period beginning January 1, 2023, including interim periods within that annual reporting period. The standard will apply as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The Company is in the process of evaluating the impact the adoption of this pronouncement will have on the Company’s condensed consolidated financial statements and disclosures.

Note 3. Business Combination

On February 12, 2021 (the “Closing Date”), the Company consummated the previously announced business combination (the “Business Combination”) pursuant to the terms of the Business Combination Agreement, dated as of November 19, 2020 (the “Business Combination Agreement”), by and among Longview, Clay Merger Sub, Inc., a Delaware corporation incorporated on November 12, 2020 (“Merger Sub”), and Butterfly Network, Inc., a Delaware corporation (“Legacy Butterfly”).

Immediately upon the consummation of the Business Combination and the other transactions contemplated by the Business Combination Agreement (collectively, the “Transactions”, and such completion, the “Closing”), Merger Sub merged with and into Legacy Butterfly, with Legacy Butterfly surviving the Business Combination as a wholly-owned subsidiary of Longview (the “Merger”). In connection with the Transactions, Longview changed its name to “Butterfly Network, Inc.” and Legacy Butterfly changed its name to “BFLY Operations, Inc.”

The Merger is accounted for as a reverse recapitalization in accordance with U.S. GAAP primarily due to the fact that Legacy Butterfly stockholders continue to control the Company following the closing of the Business Combination. Under this method of accounting, Longview is treated as the “acquired” company for accounting purposes and the Business Combination is treated as the equivalent of Legacy Butterfly issuing stock for the net assets of Longview, accompanied by a recapitalization. The net assets of Longview will be stated at historical cost, with no goodwill or other intangible assets recorded. Reported shares and earnings per share available to holders of the Company’s capital stock and equity awards prior to the Business Combination have been retroactively restated reflecting the exchange ratio established pursuant to the Business Combination Agreement (1:1.0383).

Pursuant to the Merger, at the Effective Time of the Merger (the “Effective Time”):


	•	each share of Legacy Butterfly capital stock (other than the Legacy Butterfly Series A preferred stock) that was issued and outstanding immediately prior to the Effective Time was automatically canceled and converted into the right to receive 1.0383 shares of the Company’s Class A common stock, rounded down to the nearest whole number of shares;


	•	each share of Legacy Butterfly Series A preferred stock that was issued and outstanding immediately prior to the Effective Time was automatically canceled and converted into the right to receive 1.0383 shares of the Company’s Class B common stock, rounded down to the nearest whole number of shares;

•

each option to purchase shares of Legacy Butterfly common stock, whether vested or unvested, that was outstanding and unexercised as of immediately prior to the Effective Time was assumed by the Company and became an option (vested or unvested, as applicable) to purchase a number of shares of the Company’s Class A common stock equal to the number of shares of Legacy Butterfly common stock subject to such option immediately prior to the Effective Time multiplied by 1.0383, rounded down to the nearest whole number of

Table of Contents

shares, at an exercise price per share equal to the exercise price per share of such option immediately prior to the Effective Time divided by 1.0383 and rounded up to the nearest whole cent;

•

each Legacy Butterfly restricted stock unit outstanding immediately prior to the Effective Time was assumed by the Company and became a restricted stock unit with respect to a number of shares of the Company’s Class A common stock, rounded to the nearest whole share, equal to the number of shares of Legacy Butterfly common stock subject to such Legacy Butterfly restricted stock unit immediately prior to the Effective Time multiplied by 1.0383; and


	•	the principal amount plus accrued but unpaid interest, if any, on the Legacy Butterfly convertible notes outstanding as of immediately prior to the Effective Time was automatically canceled and converted into the right to receive shares of the Company’s Class A common stock, with such shares of the Company’s Class A common stock calculated by dividing the outstanding principal plus accrued interest, if any, of each Legacy Butterfly convertible note by $10.00, rounded down to the nearest whole number of shares.

In addition, on February 12, 2021, Longview filed the Second Amended and Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware, which became effective simultaneously with the Effective Time. As a consequence of filing the Restated Certificate, the Company adopted a dual class structure, comprised of the Company’s Class A common stock, which is entitled to one vote per share, and the Company’s Class B common stock, which is entitled to 20 votes per share. The Company’s Class B common stock is subject to a “sunset” provision if Jonathan M. Rothberg, Ph.D., the founder of Legacy Butterfly and Chairman of the Company (“Dr. Rothberg”), and other permitted holders of the Company’s Class B common stock collectively cease to beneficially own at least twenty percent (20%) of the number of shares of the Company’s Class B common stock (as such number of shares is equitably adjusted in respect of any reclassification, stock dividend, subdivision, combination or recapitalization of the Company’s Class B common stock) collectively held by Dr. Rothberg and permitted transferees of the Company’s Class B common stock as of the Effective Time.

In addition, concurrently with the execution of the Business Combination Agreement, on November 19, 2020, Longview entered into subscription agreements (the “Subscription Agreements”) with certain institutional investors (the “PIPE Investors”), pursuant to which the PIPE Investors purchased, immediately prior to the Closing, an aggregate of 17,500,000 shares of Longview Class A common stock at a purchase price of $10.00 per share (the “PIPE Financing”).

The total number of shares of the Company’s Class A common stock outstanding immediately following the Closing was approximately 164,862,470, comprising:

59
	•	95,633,659 shares of the Company’s Class A common stock issued to Legacy Butterfly stockholders (other than certain holders of Legacy Butterfly Series A preferred stock) and holders of Legacy Butterfly convertible notes in the Merger;


	•	17,500,000 shares of the Company’s Class A common stock issued in connection with the Closing to the PIPE Investors pursuant to the PIPE Financing;

	•	10,350,000 shares of the Company’s Class A common stock issued to holders of shares of Longview Class B common stock outstanding at the Effective Time; and
	•	41,378,811 shares of the Company’s Class A common stock held by holders of Longview Class A common stock outstanding at the Effective Time.

Table of Contents

The total number of shares of the Company’s Class B common stock issued at the Closing was approximately 26,426,937. Immediately following the Closing, Dr. Rothberg held approximately 76.2% of the combined voting power of the Company. Accordingly, Dr. Rothberg and his permitted transferees control the Company and the Company is a controlled company within the meaning of the corporate governance standards of the New York Stock Exchange (the “NYSE”).

The most significant change in the post-combination Company’s reported financial position and results was an increase in cash of $589.5 million. The Company as the accounting acquirer incurred $11.4 million in transaction costs relating to the Business Combination, which has been offset against the gross proceeds recorded in additional paid-in capital in the condensed consolidated statements of changes in convertible preferred stock and stockholders’ equity (deficit). The Company on the date of Closing used proceeds of the Transactions to pay off $30.9 million, representing all significant liabilities of the acquiree excluding the warrant liability. As of the date of the Closing, the Company recorded net liabilities of $186.5 million with a corresponding offset to additional paid-in capital. The net liabilities include warrant liabilities of $187.3 million and other insignificant assets and liabilities. The Company received proceeds of $0.6 million related to other transactions that occurred at the same time as the Business Combination.

Note 4. Revenue Recognition

Disaggregation of Revenue

The Company disaggregates revenue from contracts with customers by product type and by geographical market. The Company believes that these categories aggregate the payor types by nature, amount, timing and uncertainty of their revenue streams. The following table summarizes the Company’s disaggregated revenues (in thousands) for the three and nine months ended September 30, 2021 and 2020:


	Pattern of	Three months ended September 30,				Nine months ended September 30,
	Recognition	2021		2020		2021		2020
By Product Type:
Devices and accessories	Point-in-time	$	10,848	$	8,621	$	33,455	$	25,820
Subscription services and other services	Over time		3,773		1,514		10,123		4,777
Total revenue		$	14,621	$	10,135	$	43,578	$	30,597
By Geographical Market:
United States		$	10,220	$	7,453	$	30,320	$	22,021
International			4,401		2,682		13,258		8,576
Total revenue		$	14,621	$	10,135	$	43,578	$	30,597

Contract Balances

Contract balances represent amounts presented in the condensed consolidated balance sheets when either the Company has transferred goods or services to the customer, or the customer has paid consideration to the Company under the contract. These contract balances include trade accounts receivable and deferred revenue. Deferred revenue represents cash consideration received from customers for services that are transferred to the customer over the respective subscription period. The accounts receivable balances represent amounts billed to customers for goods and services where the Company has an unconditional right to payment of the amount billed.

The following table provides information about receivables and deferred revenue from contracts with customers (in thousands):


	September 30,		December 31,
	2021		2020
Accounts receivable, net	$	9,538	$	5,752
Deferred revenue, current		12,015		8,443
Deferred revenue, non-current		4,878		2,790

Table of Contents

The Company recognizes a receivable when it has an unconditional right to payment, and payment terms are typically 30 days for all product and service sales. The allowance for doubtful accounts was $0.4 million and $0.6 million as of September 30, 2021 and December 31, 2020, respectively.

The amount of revenue recognized during the three months ended September 30, 2021 and 2020 that was included in the deferred revenue balance at the beginning of the period was $4.3 million and $0.9 million, respectively. The amount of revenue recognized during the nine months ended September 30, 2021 and 2020 that was included in the deferred revenue balance at the beginning of the period was $7.2 million and $2.8 million, respectively.

The Company incurs incremental costs of obtaining contracts and costs of fulfilling contracts with customers. The amount of costs capitalized during the three and nine months ended September 30, 2021 and 2020 was not significant.

Transaction Price Allocated to Remaining Performance Obligations

On September 30, 2021, the Company had $21.8 million of remaining performance obligations. The Company expects to recognize 60% of its remaining performance obligations as revenue in the next twelve months, and an additional 40% thereafter.

Note 5. Fair Value of Financial Instruments

Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of significant judgment, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair value.

The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

●

Level 1 — Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access.

●

Level 2 — Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.

●

Level 3 — Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company has no assets or liabilities valued with Level 3 inputs.

The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximates their fair values due to the short-term or on-demand nature of these instruments.

There were no transfers between fair value measurement levels during the periods ended September 30, 2021 and December 31, 2020.

The Company determined the fair value of its Public Warrants as Level 1 financial instruments, as they are traded in active markets. Because any transfer of Private Warrants from the initial holder of the Private Warrants would result in the Private Warrants having substantially the same terms as the Public Warrants, management determined that the fair value of each Private Warrant is the same as that of a Public Warrant. Accordingly, the Private Warrants are classified as Level 2 financial instruments.

Table of Contents

The following table summarizes the Company’s assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy (in thousands):


			Fair Value Measurement Level
	Total		Level 1		Level 2		Level 3
September 30, 2021:
Marketable securities:
Mutual funds	$	315,099	$	315,099	$	—	$	—
Total assets at fair value on a recurring basis	$	315,099	$	315,099	$	—	$	—

Warrants:
Public Warrants	$	37,949	$	37,949	$	—	$	—
Private Warrants		18,847		—		18,847		—
Total liabilities at fair value on a recurring basis	$	56,796	$	37,949	$	18,847	$	—

The Company did not have any assets or liabilities similar to those above requiring fair value measurement at December 31, 2020.

Note 6. Inventories

A summary of inventories is as follows at September 30, 2021 and December 31, 2020 (in thousands):


	September 30,		December 31,
	2021		2020
Raw materials	$	8,269		7,688
Work-in-progress		1,146		865
Finished goods		14,405		17,252
Total inventories	$	23,820	$	25,805

Work-in-progress represents inventory items in intermediate stages of production by third-party manufacturers. For the three and nine months ended September 30, 2021, net realizable value inventory adjustments and excess and obsolete inventory charges were $0.6 million and $0.6 million, respectively, and were recognized in product cost of revenues. During fiscal 2021, the Company utilized $35.0 million of the accrued purchase commitment liability to reduce the value of inventory purchased under its minimum commitment in the supply arrangement. This is disclosed in Note 16 “Commitments and Contingencies”. For the three and nine months ended September 30, 2020, net realizable value inventory adjustments and excess and obsolete inventory charges were $6.3 million and $6.9 million, respectively, and were recognized in product cost of revenues.

Note 7. Non-Current Assets

The Company’s property and equipment, net consists of the following at September 30, 2021 and December 31, 2020 (in thousands):


	September 30,		December 31,
	2021		2020
Property and equipment, gross	$	14,160	$	10,268
Less: accumulated depreciation and amortization		(4,792)		(3,398)
Property and equipment, net	$	9,368	$	6,870

Table of Contents

Other non-current assets consist of the following at September 30, 2021 and December 31, 2020 (in thousands):


	September 30,		December 31,
	2021		2020
Security deposits	$	1,883	$	1,888
Restricted cash		4,000		—
Deferred offering costs		—		3,711
Other long-term assets		955		—
Total other non-current assets	$	6,838	$	5,599

Note 8. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following at September 30, 2021 and December 31, 2020 (in thousands):


	September 30,		December 31,
	2021		2020
Employee compensation	$	12,942	$	5,968
Customer deposits		1,174		1,177
Accrued warranty liability		303		646
Non-income tax		2,341		3,695
Professional fees		2,920		5,432
Vendor settlements		—		2,975
Other		3,129		2,069
Total accrued expenses and other current liabilities	$	22,809	$	21,962

Warranty expense activity for the three and nine months ended September 30, 2021 and 2020 is as follows (in thousands):


	Three months ended September 30,				Nine months ended September 30,
	2021		2020		2021		2020
Balance, beginning of period	$	1,161	$	1,524	$	1,826	$	876
Warranty provision charged to operations		123		526		(103)		2,037
Warranty claims		(168)		(342)		(607)		(1,205)
Balance, end of period	$	1,116	$	1,708	$	1,116	$	1,708

The Company classifies its accrued warranty liability based on the timing of expected warranty activity. The future costs of expected activity greater than one year is recorded within other non-current liabilities on the condensed consolidated balance sheet.

Note 9. Convertible Preferred Stock

The Company has issued four series of Convertible Preferred Stock, Series A through Series D. The following table summarizes the authorized, issued and outstanding Convertible Preferred Stock of the Company as of immediately prior to the Business Combination and December 31, 2020 (in thousands, except share and per share information):


		Issuance		Shares	Total						Initial
		Price		Authorized,	Proceeds or				Net		Liquidation
	Year of	per		Issued and	Exchange		Issuance		Carrying		Price per
Class	Issuance	share		Outstanding	Value		Costs		Value		share
Series A	2012	$	0.04	26,946,090	$	1,038	$	11	$	1,027	$	0.77
Series B	2014		0.77	25,957,500		20,000		99		19,901		0.77
Series C	2014 – 2015		3.21	29,018,455		93,067		246		92,821		3.21
Series D	2018		9.89	25,275,073		250,000		2,812		247,188		9.89
				107,197,118

Table of Contents

Prior to the completion of the Business Combination there were no significant changes to the terms of the Convertible Preferred Stock. Upon the Closing of the Business Combination, the Convertible Preferred stock converted into the right to receive Class A and Class B common stock based on the Business Combination’s conversion ratio of 1.0383 of the Company’s shares for each Legacy Butterfly share. The Company recorded the conversion at the carrying value of the Convertible Preferred Stock at the time of Closing. There are no shares of Convertible Preferred Stock outstanding as of September 30, 2021.

Note 10. Equity Incentive Plans

The Company’s 2012 Employee, Director and Consultant Equity Incentive Plan (the “2012 Plan”) was adopted by its Board of Directors and stockholders in March 2012. The Butterfly Network, Inc. Amended and Restated 2020 Equity Incentive Plan (the “2020 Plan”) was approved by the Board of Directors in the fourth quarter of 2020 and by the stockholders in the first quarter of 2021. Grants under the 2012 Plan and 2020 Plan are included in the tables below.

In connection with the Closing of the Business Combination, the Company adjusted the equity awards as described in Note 3 “Business Combination”. The adjustments to the awards did not result in incremental expense as the equitable adjustments were made pursuant to a preexisting, nondiscretionary anti-dilution provision in the 2012 Plan, and the fair-value, vesting conditions and classification of the awards are the same immediately before and after the modification.

Stock option activity

The following table summarizes the changes in the Company’s outstanding stock options for the nine months ended September 30, 2021:


		Number of
		Options
Outstanding at December 31, 2020		26,708,329
Granted		7,436,366
Exercised		(8,283,862)
Forfeited		(8,690,193)
Outstanding at September 30, 2021		17,170,640

Each award will vest based on continued service which is generally over 3-4 years. The grant date fair value of the award will be recognized as stock-based compensation expense over the requisite service period. The grant date fair value was determined using similar methods and assumptions as those previously disclosed by the Company.

On January 23, 2021, the former Chief Executive Officer and member of the Board of Directors of Legacy Butterfly resigned from his position as Chief Executive Officer. Pursuant to the separation agreement between the former Chief Executive Officer and Legacy Butterfly, the former officer received equity-based compensation. The equity compensation includes the acceleration of vesting of the officer’s service-based options. The acceleration of 1.6 million options was pursuant to the original option award agreement. The Company recognized $2.6 million of expense related to the acceleration of this option award during the nine months ended September 30, 2021. No expense related to the acceleration of this option award was recognized during the three months ended September 30, 2021.

Table of Contents

Restricted stock unit (“RSU”) activity

The following table summarizes the changes in the Company’s outstanding restricted stock units for the nine months ended September 30, 2021:


		Number of
		RSUs
Outstanding at December 31, 2020		1,894,897
Granted		3,274,079
Vested		(597,021)
Forfeited		(128,650)
Outstanding at September 30, 2021		4,443,305

Included in the table above are service-based restricted stock units. During the nine months ended September 30, 2021, the Company granted 2.2 million service-based awards. Each award will vest based on continued service which is generally over 3-4 years. The grant date fair value of the award will be recognized as stock-based compensation expense over the requisite service period. The fair value of restricted stock units was estimated on the date of grant based on the fair value of the Company’s Class A common stock.

Included in the table above are performance-based restricted stock units that include certain service conditions in the award. In January 2021, the Company granted 1.0 million restricted stock units to certain executives. In 2020, the Company granted 1.9 million restricted stock units to certain employees and consultants, including a grant of 1.0 million restricted stock units to the Chairman of the Board and significant shareholder of Butterfly. The service condition for these awards is satisfied by providing service to the Company based on the defined service period per the award agreement. The performance-based condition is satisfied upon the occurrence of a business combination event as defined in the award agreement. The achievement of the performance condition was deemed satisfied in the first quarter of 2021, when the completion of the Business Combination occurred.

The fair value of performance-based restricted stock units was estimated on the date of grant based on the fair value of the Company’s Class A common stock. For each award, the Company recognizes the expense over the requisite service period as defined in the award agreement. During the nine months ended September 30, 2021, the Company recognized the full grant date fair value of the awards granted to the Chairman of the Board and one other consultant as service to the Company was no longer required since the Business Combination closed in the first quarter of 2021. No expense for these awards was recognized during the three months ended September 30, 2021. For the remaining awards, continued service is still required for the awards to continue to vest per the award agreements.

In the third quarter of 2021 and excluded from the table above, the Company approved 0.1 million performance-based restricted stock units for certain executives. The service condition for these awards is satisfied by providing service to the Company based on the defined service period per the award agreement. The performance-based conditions are objective and subjective performance metrics defined in the award agreement. Each award agreement provides that the Compensation Committee of the Board of Directors (the “Compensation Committee”) has discretion over the number of shares that will vest pursuant to the performance metrics. During the first quarter of the year ending December 31, 2023, the Compensation Committee will certify the number of shares vested under the performance-based restricted stock unit awards. The Company concluded a grant date has not occurred and that the service inception date precedes the grant date. For awards that management estimates will vest, the expense is recognized using the accelerated attribution method over the requisite service period as defined in the award agreement. The fair value of these awards is remeasured at the close of each reporting period until a grant date occurs. An insignificant amount of expense for these awards was recognized during the three and nine months ended September 30, 2021.

Table of Contents

The Company’s total stock-based compensation expense for all stock option and restricted stock unit awards for the periods presented was as follows (in thousands):


	Three months ended September 30,				Nine months ended September 30,
	2021		2020		2021		2020
Cost of revenue – subscription	$	6	$	2	$	9	$	12
Research and development		3,552		955		6,502		3,391
Sales and marketing		2,484		456		6,243		1,482
General and administrative		4,692		966		26,015		2,842
Total stock-based compensation expense	$	10,734	$	2,379	$	38,769	$	7,727

Note 11. Net Loss Per Share

We compute net loss per share of Class A and Class B common stock using the two-class method. Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of each class of the Company’s common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential shares of the Company’s common stock, including those presented in the table below, to the extent dilutive. Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of the Company’s common stock outstanding would have been anti-dilutive. Since the Company was in a net loss position for all periods presented, the basic earnings per share (“EPS”) calculation excludes preferred stock as it does not participate in net losses of the Company.

As the Company uses the two-class method required for companies with multiple classes of common stock, the following table presents the calculation of basic and diluted net loss per share for each class of the Company’s common stock outstanding (in thousands, except share and per share amounts):


Three months ended September 30, 2021
					Total
	Class A		Class B		Common Stock
Numerator:
Allocation of undistributed earnings	$	(11,733)	$	(1,828)	$	(13,561)
Numerator for basic and diluted EPS – loss available to common stockholders	$	(11,733)	$	(1,828)	$	(13,561)
Denominator:
Weighted-average common shares outstanding		169,668,255		26,426,937		196,095,192
Denominator for basic and diluted EPS – weighted-average common stock		169,668,255		26,426,937		196,095,192
Basic and diluted loss per share	$	(0.07)	$	(0.07)	$	(0.07)


Three months ended September 30, 2020
					Total
	Class A		Class B		Common Stock
Numerator:
Allocation of undistributed earnings	$	(92,208)	$	—	$	(92,208)
Numerator for basic and diluted EPS – loss available to common stockholders	$	(92,208)	$	—	$	(92,208)
Denominator:
Weighted-average common shares outstanding		6,066,117		—		6,066,117
Denominator for basic and diluted EPS – weighted-average common stock		6,066,117		—		6,066,117
Basic and diluted loss per share	$	(15.20)	$	—	$	(15.20)

Table of Contents


Nine months ended September 30, 2021
					Total
	Class A		Class B		Common Stock
Numerator:
Allocation of undistributed earnings	$	(14,872)	$	(2,321)	$	(17,193)
Numerator for basic and diluted EPS – loss available to common stockholders	$	(14,872)	$	(2,321)	$	(17,193)
Denominator:
Weighted-average common shares outstanding		143,295,154		22,361,254		165,656,408
Denominator for basic and diluted EPS – weighted-average common stock		143,295,154		22,361,254		165,656,408
Basic and diluted loss per share	$	(0.10)	$	(0.10)	$	(0.10)


Nine months ended September 30, 2020
					Total
	Class A		Class B		Common Stock
Numerator:
Allocation of undistributed earnings	$	(139,803)	$	—	$	(139,803)
Numerator for basic and diluted EPS – loss available to common stockholders	$	(139,803)	$	—	$	(139,803)
Denominator:
Weighted-average common shares outstanding		6,026,658		—		6,026,658
Denominator for basic and diluted EPS – weighted-average common stock		6,026,658		—		6,026,658
Basic and diluted loss per share	$	(23.20)	$	—	$	(23.20)

For the periods presented above, the net loss per share amounts are the same for Class A and Class B common stock because the holders of each class are entitled to equal per share dividends or distributions in liquidation in accordance with the Certificate of Incorporation. The undistributed earnings for each year are allocated based on the contractual participation rights of the Class A and Class B common stock as if the earnings for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed earnings are allocated on a proportionate basis.

For the periods presented, anti-dilutive common equivalent shares were as follows:


	September 30,
	2021	2020
Outstanding options to purchase common stock	17,170,640	25,280,487
Outstanding restricted stock units	3,932,587	—
Outstanding warrants	20,652,937	—
Outstanding convertible preferred stock (Series A through D)	—	107,197,118
Total anti-dilutive common equivalent shares	41,756,164	132,477,605

Note 12. Related Party Transactions

Prior to the Closing of the Business Combination, there were no significant changes in the nature of the Company’s related party transactions since December 31, 2020. Pursuant to a First Addendum dated November 19, 2020 to the Amended and Restated Technology Services Agreement dated November 11, 2020 by and between the Company, 4Catalyzer Corporation (“4Catalyzer”), and other participant companies controlled by Dr. Rothberg (the “ARTSA”), Butterfly terminated its participation under the ARTSA immediately prior to the Effective Time of the Business Combination.

Table of Contents

A summary of related-party transactions and balances with 4Catalyzer are as follows (in thousands):


	Three months ended September 30,				Nine months ended September 30,
	2021		2020		2021		2020
Total incurred for operating expenses	$	18	$	1,198	$	559	$	4,265

Note 13. Loan Payable

In May 2020, the Company received loan proceeds of $4.4 million under the Paycheck Protection Program (“PPP”). The Company used the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities. The Company accounted for the loan as debt. Following the Closing of the Business Combination discussed in Note 3 “Business Combination”, the Company repaid the loan in full in February 2021. The Company recognized an insignificant amount of interest expense in the condensed consolidated statement of operations and comprehensive loss related to the loan.

Note 14. Convertible Debt

In the year ended December 31, 2020, the Company issued convertible debt for total gross proceeds of $50.0 million.

Pursuant to the terms of the debt, at the Effective Time of the Merger discussed in Note 3 “Business Combination”, the convertible debt was automatically cancelled and converted into the right to receive shares of the Company’s Class A common stock. The debt was converted with $49.9 million, the net carrying value of the debt as of the Closing of the Business Combination, in stockholders’ equity with a corresponding decrease to the convertible debt for the principal, accrued interest and unamortized debt issuance costs in the condensed consolidated balance sheet.

The Company recorded interest expense and amortization expense for the issuance costs of $0.6 million and $0.4 million for the nine months ended September 30, 2021 and 2020, respectively. The Company recorded interest expense and amortization expense for the issuance costs of $0.0 million and $0.3 million for the three months ended September 30, 2021 and 2020, respectively.

Note 15. Warrants

Public Warrants

The Company issued Public Warrants and Private Warrants in connection with its IPO. As of September 30, 2021, there were an aggregate of 13,799,604 outstanding Public Warrants, which entitle the holder to acquire Class A common stock. During the three and nine months ended September 30, 2021, the amount of exercises of Public Warrants was not significant. The amount reclassified into equity upon the exercise of the Public Warrants was not significant. Each whole warrant entitles the registered holder to purchase one share of Class A common stock at an exercise price of $11.50 per share, subject to adjustment as discussed below, beginning on May 26, 2021. The warrants will expire on February 12, 2026 or earlier upon redemption or liquidation.

Redemptions

At any time while the warrants are exercisable, Butterfly may redeem not less than all of the outstanding Public Warrants:

●

at a price of $0.01 per warrant;

●

upon a minimum of 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder;

Table of Contents

●

provided that the last reported sale price of the Class A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like and for certain issuances of Class A common stock and equity-linked securities) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date Butterfly sends the notice of redemption to the warrant holders; and

●

provided that there is an effective registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants, and a current prospectus relating thereto, available through the 30-day redemption period or Butterfly has elected to require the exercise of the warrants on a “cashless basis” (as described below).

If the foregoing conditions are satisfied and the Company issues a notice of redemption of the Public Warrants at $0.01 per warrant, each holder of Public Warrants will be entitled to exercise his, her or its Public Warrants prior to the scheduled redemption date.

If the Company calls the Public Warrants for redemption for $0.01 as described above, the Company’s Board of Directors may elect to require any holder that wishes to exercise his, her or its Public Warrant to do so on a “cashless basis.” If the Company’s Board of Directors makes such election, all holders of Public Warrants would pay the exercise price by surrendering their warrants for that number of shares of Class A common stock equal to the quotient obtained by dividing (x) the product of the number of shares of Class A common stock underlying the warrants, multiplied by the excess of the “fair market value” over the exercise price of the warrants by (y) the “fair market value.” For purposes of the redemption provisions of the warrants, the “fair market value” means the average last reported sale price of the Class A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants.

Commencing 90 days after the warrants become exercisable, Butterfly may redeem not less than all of the outstanding Public Warrants and Private Warrants:

●

at $0.10 per warrant;

●

upon a minimum of 30 days’ prior written notice of redemption;

●

provided that the last reported sale price of the Class A common stock equals or exceeds $10.00 per share (as adjusted per stock splits, stock dividends, reorganizations, reclassifications, recapitalizations and the like) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders;

●

provided that the Private Warrants are also concurrently exchanged at the same price (equal to a number of shares of Class A common stock) as the outstanding Public Warrants; and

●

provided that there is an effective registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and a current prospectus relating thereto available throughout the 30-day redemption period.

If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants at $0.10 per warrant, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date on a cashless basis and receive that number of shares based on the redemption date and the “fair market value” of the Class A common stock, in accordance with a table set forth in the warrant agreement.

The Company evaluated the Public Warrants under ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, in conjunction with the SEC Division of Corporation Finance’s April 12, 2021 Public Statement, Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”), and concluded that they do not meet the criteria to be classified in stockholders’ equity. Specifically, the exercise of the warrants may be settled in cash upon the occurrence of a tender offer or exchange offer in which the maker of the tender offer or exchange offer, upon completion of the tender offer or exchange offer, beneficially owns more than 50% of the outstanding shares of the Company’s Class A common stock, even if it would not result in a change of control of the Company. This provision would preclude the warrants from being classified in equity and thus the warrants should be classified as a liability.

Table of Contents

Private Warrants

As of September 30, 2021, there were 6,853,333 Private Warrants outstanding. There have been no exercises of the Private Warrants. The Private Warrants are identical to the Public Warrants, except that so long as they are held by Longview Investors LLC (the “Sponsor”) or any of its permitted transferees, (i) the Private Warrants and the shares of Class A common stock issuable upon the exercise of the Private Warrants are not transferable, assignable or saleable until 30 days after the completion of the Business Combination, (ii) the Private Warrants will be exercisable for cash or on a cashless basis, at the holder’s option, and (iii) the Private Warrants are not subject to Butterfly’s redemption option at the price of $0.01 per warrant. The Private Warrants are subject to Butterfly’s redemption option at the price of $0.10 per warrant, provided that the other conditions of such redemption are met, as described above. If the Private Warrants are held by a holder other than the Sponsor or any of its permitted transferees, the Private Warrants will be redeemable by the Company in all redemption scenarios applicable to the Public Warrants and exercisable by such holders on the same basis as the Public Warrants.

The Company evaluated the Private Warrants under ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, in conjunction with the SEC Division of Corporation Finance’s April 12, 2021 Public Statement, Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”), and concluded that they do not meet the criteria to be classified in stockholders’ equity. Specifically, the terms of the warrants provide for potential changes to the settlement amounts dependent upon the characteristics of the warrant holder, and, because the holder of a warrant is not an input into the pricing of a fixed-for-fixed option on equity shares, such provision would preclude the warrant from being classified in equity and thus the warrants should be classified as a liability.

The Company recognized a gain of $43.0 million and $130.5 million as a change in fair value of warrant liabilities in the condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2021, respectively.

Note 16. Commitments and Contingencies

Commitments

Operating leases:

The Company leases office space under operating leases. Minimum rental payments under operating leases are recognized on a straight-line basis over the term of the lease. Rent expense under operating leases was $0.9 million and $0.5 million in the three months ended September 30, 2021 and 2020, respectively. Rent expense under operating leases was $2.0 million and $1.3 million in the nine months ended September 30, 2021 and 2020, respectively. The Company had $7.2 million and $1.0 million of long-term deferred rent related to its operating leases as of September 30, 2021 and December 31, 2020, respectively. Long-term deferred rent is recorded in other non-current liabilities on the condensed consolidated balance sheet.

In May 2021, the Company entered into a lease arrangement for office space in Burlington, MA which expires in September 2032 and includes approximately $27.3 million of legally binding minimum lease payments. As stated in the agreement, the Company and the landlord agreed to a payment schedule that includes escalating rent payments beginning on the lease commencement date. The lease contains a tenant improvement allowance of $5.2 million, which is recognized as a reduction of minimum lease payments and recognized on a straight-line basis over the term of the lease. The lease also includes termination and renewal options to be exercised at the discretion of the Company. These options are not reflected in the lease term as it is not reasonably assured that they will be exercised. The Company gained access to the office space and began recognizing rent expense for the lease in the third quarter of 2021. Rent expense for the lease was $0.3 million in the three and nine months ended September 30, 2021.

In the second quarter of 2021, the Company delivered a $4.0 million letter of credit for the Burlington, MA lease, secured by a deposit of the same amount with a financial institution that issued the letter of credit. The deposit is classified as restricted cash and included in other non-current assets on the condensed consolidated balance sheets.

Table of Contents

The following is a schedule of future minimum rental payments under non-cancelable operating leases with initial terms in excess of one year (in thousands):


Years ending December 31:
Remainder of 2021	$	298
2022		2,453
2023		3,832
2024		4,528
2025		4,672
Thereafter		27,081
Total future minimum rental payments	$	42,864

Purchase commitments:

The Company enters into inventory purchase commitments with third-party manufacturers in the ordinary course of business. These commitments are generally non-cancellable and are based on sales forecasts. These agreements range from one to five-year periods and may contain fixed or minimum annual commitments, subject to certain provisions that allow the Company to renegotiate the commitment. The aggregate amount of minimum inventory purchase commitments as of September 30, 2021 was $129.5 million.

During 2019, the Company entered into an inventory supply agreement with a certain third-party manufacturing vendor. In November 2020, the Company and the vendor amended the 2019 inventory supply arrangement. The amended agreement included provisions to increase the aggregate purchase commitments to $169.3 million and extend the time frame of the agreement to December 2022. The provisions of the agreement also allow the Company, once the defined cumulative purchase threshold per the agreement is reached, to pay for a portion of the subsequent inventory purchases using the vendor advance.

During the three and nine months ended September 30, 2021, the Company recognized a net loss and additional accrued liability for the vendor purchase commitment of $11.6 million. During the three and nine months ended September 30, 2021, the Company utilized $35.0 million of the accrued purchase commitment liability to reduce the value of inventory purchased under its minimum commitment in the supply arrangement. During the three and nine months ended September 30, 2020, the Company recognized a net loss on the vendor purchase commitment of $56.4 million, as an estimate of future excess inventory from its supply arrangement.

The Company applied the guidance in Topic 330, Inventory, to assess the purchase commitment and related loss. The Company considered a variety of factors and data points when determining the existence and scope of a loss for the minimum purchase commitment. The factors and data points included Company-specific forecasts which are reliant on the Company’s limited sales history, agreement-specific provisions, macroeconomic factors and market and industry trends. Determining the loss is subjective and requires significant management judgment and estimates. Future events may differ from those assumed in the Company’s assessment, and therefore the loss may change in the future.

As of September 30, 2021, the Company has a prepaid advance of $36.4 million, net of write-downs and an accrual of $19.5 million related to the agreement. The portion of the balances that is expected to be utilized in the next 12 months is included in current assets and current liabilities in the accompanying condensed consolidated balance sheets.

Other commitments:

The Company sponsors a 401(k) defined contribution plan covering all eligible U.S. employees. Contributions to the 401(k) plan are discretionary. The Company did not make any matching contributions to the 401(k) plan for the periods ended September 30, 2021 and December 31, 2020.

Contingencies

The Company is involved in litigation and legal matters from time to time, which have arisen in the normal course of business. Although the ultimate results of these matters are not currently determinable, management does not expect that

Table of Contents

they will have a material effect on the Company’s condensed consolidated balance sheets, statements of operations and comprehensive loss, or statements of cash flows.

On December 14, 2020, Nidhish Nair, a purported stockholder of Longview, filed a lawsuit in the Supreme Court of the State of New York, County of New York, captioned Nair v. Longview Acquisition Corp., against Longview and the members of its Board of Directors (the “Nair Complaint”). On December 16, 2020, Eric Lau, a purported stockholder of Longview, filed a lawsuit in the Supreme Court of the State of New York, County of New York, captioned Lau v. Longview Acquisition Corp., against Longview, the members of its Board of Directors, and Legacy Butterfly (the “Lau Complaint”). The Nair Complaint and the Lau Complaint, which are referred to collectively as the Complaints, asserted a breach of fiduciary duty claim against the individual defendants and an aiding and abetting claim against Longview in connection with the Business Combination between Longview and Legacy Butterfly. The Lau Complaint also asserted an aiding and abetting claim against Legacy Butterfly. The Complaints alleged, among other things, that (i) defendants engaged in an unfair sales process and agreed to inadequate consideration in connection with the Business Combination, and (ii) that the Registration Statement on Form S-4 filed with the SEC on November 27, 2020 in connection with the Business Combination was materially misleading. The Complaints sought, among other things, to enjoin the Business Combination, rescind the transaction or award rescissory damages to the extent it is consummated, and an award of attorneys’ fees and expenses. The Nair Complaint was voluntarily dismissed on February 21, 2021, and the Lau Complaint was voluntarily dismissed on March 2, 2021. During the second quarter of 2021, the Company paid an insignificant amount to resolve plaintiffs’ requests for an attorney fee award.

The Company enters into agreements that contain indemnification provisions with other parties in the ordinary course of business, including business partners, investors, contractors, customers and the Company’s officers, directors and certain employees. The Company has agreed to indemnify and defend the indemnified party claims and related losses suffered or incurred by the indemnified party from actual or threatened third-party claims because of the Company’s activities or non-compliance with certain representations and warranties made by the Company. It is not possible to determine the maximum potential loss under these indemnification provisions due to the Company’s limited history of prior indemnification claims and the unique facts and circumstances involved in any particular case. To date, losses recorded in the Company’s condensed consolidated statements of operations and comprehensive loss in connection with the indemnification provisions have not been material.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of our condensed consolidated results of operations and financial condition. The discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto contained in this Quarterly Report on Form 10-Q and the consolidated financial statements and notes thereto for the year ended December 31, 2020 contained in Amendment No. 2 to the Current Report on Form 8-K filed with the SEC on March 29, 2021. This discussion contains forward-looking statements and involves numerous risks and uncertainties, including, but not limited to, those described in the “Risk Factors” sections of our Annual Report on Form 10-K for the year ended December 31, 2020, as amended, and of this Quarterly Report on Form 10-Q. Actual results may differ materially from those contained in any forward-looking statements. Unless the context otherwise requires, references to “we”, “us”, “our”, and “the Company” are intended to mean the business and operations of Butterfly Network, Inc. and its consolidated subsidiaries. The unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2021 and 2020, respectively, present the financial position and results of operations of Butterfly Network, Inc. and its wholly-owned subsidiaries.

Overview

We are an innovative digital health business whose mission is to democratize healthcare by making medical imaging accessible to everyone around the world. Powered by our proprietary Ultrasound-on-Chip™ technology, our solution uses a unique combination of software and hardware enabling medical imaging to drive more clinical insight at patient point-of-care. With this technology, Butterfly created the only ultrasound transducer that can perform “whole-body imaging” in a single handheld probe using semiconductor technology. After launching our first-generation Butterfly iQ hardware product in 2019, in 2020 we launched and commercialized the second-generation product, the Butterfly iQ+. Our proprietary software and artificial intelligence (“AI”) solution are intended to make the product easy to use, integrated with the clinical workflow and accessible on a user’s smartphone or tablet, as well as healthcare enterprise systems. Our portable, usable, accessible and affordable handheld solution is protected by a robust intellectual property portfolio with more than 800 patents granted or pending.

The Butterfly iQ / iQ+ is currently cleared as a Class II medical device by the U.S. Food and Drug Administration (“FDA”), received a medical device license in Canada and has the CE mark in Europe for use by health care practitioners. It is commercially available in over 20 countries including the United States, Canada, Australia, New Zealand and throughout greater Europe.

We are focused on driving the adoption of our handheld solution in order to democratize healthcare globally. We believe that the potential global addressable ultrasound market is estimated to be $8 billion. We seek to expand the addressable market through three strategies: increasing users, expanding use cases and expanding to more care settings where the Butterfly solutions are used. We also seek to increase touchpoints with our existing and potential customers through new sales channels such as medical and nursing schools, veterinarian usage, non-governmental organizations and distributors. Generally, we currently sell directly to users through our ecommerce channel and also sell to enterprise customers through our direct sales force and distributors.

We plan to continue to invest in the development of our products and solutions across the Butterfly platform. With the launch of Butterfly iQ+, we lowered manufacturing costs and improved capabilities including lower power consumption, Needle Viz™ technology, faster frame rates and improved interoperability. Additionally, over the course of 2021, we launched multiple new software features that improve image acquisition, added features for use cases and enhanced ease of use.

While we are driving revenue growth, we are also focused on improving gross profits by working to drive operational efficiencies in our supply chain and incorporate a greater mix of higher margin products and services over time.

COVID-19

The COVID-19 pandemic that began in 2020 has created significant global economic uncertainty. Uncertainty remains regarding the extent, timing and duration of the pandemic, including the emergence of new strains of the virus that may be more contagious or virulent and the extent to which the availability of vaccines and other safety measures will positively

Table of Contents

impact public health conditions. The uncertainty and potential economic volatility impact our customer base, supply chains, our business practices and our employees.

The COVID-19 pandemic and its economic impact have caused financial strain on our customer base due to decreased funding and other revenue shortfalls. With the recent Delta variant wave of infections, we have seen our customer base become further strained in solving immediate problems associated with the variant. As a result, some of our customers have had to shift their attention to these pressing issues, resulting in decreased sales volume.

In addition, the issues originally brought on by COVID-19 continue to have an ongoing adverse impact on global supply chains, including ours. We have experienced constraints in availability, increasing lead times and costs required to obtain some inventory components. We are actively implementing new operating efficiencies in our supply chain processes to help offset the cost increases in component parts for our device.

The pandemic caused us to make modifications to our business practices, including work from home policies, establishing strict health and safety protocols for our offices specific to COVID-19 and imposing restrictions on employee travel. Our employees have resumed traveling to perform sales-generating and corporate activities, and we have opened our offices and have allowed employees at their discretion to return to our offices. We are designing and implementing a plan to allow employees to safely resume work in the office on a more regular basis.

We continue to closely monitor the developments of COVID-19 for any material impact on our business. Given the uncertainty and potential economic volatility of the impact of the COVID-19 pandemic, the recent developments we have experienced may change based on new information that may emerge concerning COVID-19, the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets.

Business Combination

On February 12, 2021 we completed the business combination with Longview (the “Business Combination”) pursuant to the terms of the Business Combination Agreement, dated as of November 19, 2020 (the “Business Combination Agreement”), by and among Longview Acquisition Corp. (“Longview”), Clay Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Butterfly Network, Inc., a Delaware corporation (“Legacy Butterfly”). The Business Combination was approved by Longview's stockholders at its special meeting held on February 12, 2021. The transaction resulted in the Company being renamed to "Butterfly Network, Inc.," Legacy Butterfly being renamed “BFLY Operations, Inc.” and the Company’s Class A common stock and warrants to purchase Class A common stock commencing trading on the New York Stock Exchange ("NYSE") on February 16, 2021 under the symbol "BFLY" and “BFLY WS”, respectively. As a result of the Business Combination, we received gross proceeds of approximately $589 million.

Recent Developments

In October 2021 we launched Butterfly iQ+ Vet, a second-generation device with sharper imaging, a new procedural guidance tool and hardware improvements that make the solution more powerful, versatile and easy-to-use for veterinarians in a variety of care settings.

Key Performance Metrics

We review the key performance measures discussed below to evaluate the business and measure performance, identify trends, formulate plans and make strategic decisions.

Units fulfilled

We define units fulfilled as the number of devices whereby control is transferred to a customer. We do not adjust this metric for returns as our volume of returns has historically been low. We view units fulfilled as a key indicator of the growth of our business. We believe that this metric is useful to investors because it presents our core growth and performance of our business period over period.

Table of Contents

Chart, waterfall chart

Description automatically generated

Units fulfilled increased by 1,609, or 40.8%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020, primarily due to increased sales from our veterinary, distributor and direct sales force revenue channels. The increased sales in these channels were offset by slowing sales in our e-commerce revenue channel.

Subscription Mix

We define subscription mix as a percentage of our total revenue recognized in a reporting period that is subscription-based, consisting primarily of our software as a service (“SaaS”) offering. We view subscription mix as a key indicator of the profitability of our business, and thus we believe that this metric is useful to investors. Because the costs and associated expenses to deliver our subscription offerings are lower as a percentage of sales than the costs of sales of our products, we believe a shift towards subscription will result in an improvement in profitability and margin expansion.

Chart, bar chart

Description automatically generated

Subscription mix increased by 10.9 percentage points, to 25.8% for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. The increase was due to an increased volume of units fulfilled and increases in subscription renewals, as well as the timing of revenue recognition for our SaaS and other subscription contracts and the timing of units fulfilled. Revenue from such contracts is deferred and recognized over the service period.

Table of Contents

Non-GAAP Financial Measures

We present non-GAAP financial measures in order to assist readers of our condensed consolidated financial statements in understanding the core operating results that our management uses to evaluate the business and for financial planning purposes. Our non-GAAP financial measures, Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA, provide an additional tool for investors to use in comparing our financial performance over multiple periods.

Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA are key performance measures that our management uses to assess our operating performance. Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA facilitate internal comparisons of our operating performance on a more consistent basis. We use these performance measures for business planning purposes and forecasting. We believe that Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA enhance an investor’s understanding of our financial performance as they are useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.

Our Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA are not prepared in accordance with U.S. GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with U.S. GAAP. When evaluating our performance, you should consider Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA alongside other financial performance measures prepared in accordance with U.S. GAAP, including gross profit, gross margin, operating loss and net loss.

Adjusted Gross Profit and Adjusted Gross Margin

We calculate Adjusted Gross Profit as gross profit adjusted to exclude depreciation and amortization, non-recurring changes to our warranty liability, non-recurring losses on purchase commitments and non-recurring inventory write-downs. We calculate Adjusted Gross Margin as gross margin adjusted to exclude depreciation and amortization, non-recurring changes to our warranty liability, non-recurring losses on purchase commitments and non-recurring inventory write-downs.

Our changes in the warranty liability are excluded from gross profit and gross margin when they are outside the normal course of operations for our business. The non-recurring warranty liability adjustments are for changes in our warranty policy resulting from a shift in product lines that impacted our estimate of future warranty costs.

We also exclude from gross profit and gross margin non-recurring losses on purchase commitments and non-recurring inventory write-downs when they are outside the normal course of business and in the period the expenses are incurred. The non-recurring losses on purchase commitments relate to inventory supply agreements where the expected losses exceed the benefit of the contracts, and the non-recurring inventory write-down adjustments are for excess and obsolete inventory resulting from a shift in product lines.

Table of Contents

The following table reconciles Adjusted Gross Profit to gross profit and Adjusted Gross Margin to gross margin, the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP.


	Three months ended September 30,				Nine months ended September 30,
	2021		2020		2021		2020
Revenue	$	14,621	$	10,135	$	43,578	$	30,597
Cost of revenue		19,743		79,386		34,064		100,519
Gross profit	$	(5,122)	$	(69,251)	$	9,514	$	(69,922)

Gross margin		(35.0)%		(683.3)%		21.8%		(228.5)%

Add:
Depreciation and amortization		131		23		291		69
Warranty liability policy change		—		—		(560)		—
Loss on purchase commitments		11,623		63,993		11,623		63,993
Inventory write-downs		582		2,570		582		2,570
Adjusted gross profit	$	7,214	$	(2,665)	$	21,450	$	(3,290)

Adjusted gross margin		49.3%		(26.3)%		49.2%		(10.8)%

Adjusted EBITDA

We calculate Adjusted EBITDA as net loss adjusted to exclude interest income, interest expense, changes in the fair value of warrant liabilities, other expense, net, provision for income taxes, stock-based compensation, depreciation and amortization and other non-recurring items. The other non-recurring items include costs related to our executive transition, adjustments for the warranty liability policy changes, discretionary transaction bonuses, non-recurring losses on purchase commitments, non-recurring inventory write-downs and other fees incurred with the close of the Business Combination.

Our non-recurring discretionary bonuses are excluded from Adjusted EBITDA when they are outside the normal course of operations for our business and were given at the discretion of management due to the completion of the Business Combination. The non-recurring costs related to the executive transition include one-time severance and bonus payments and the recruiting expenses for our current CEO. The non-recurring warranty liability adjustments are for changes in our warranty policy resulting from a shift in product lines that impacted our estimate of future warranty costs. The non-recurring losses on purchase commitments relate to inventory supply agreements where the expected losses exceed the benefit of the contracts and the non-recurring inventory write-down adjustments are for excess and obsolete inventory resulting from a shift in product lines.

Table of Contents

The following table reconciles Adjusted EBITDA to net loss, the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP.


	Three months ended September 30,				Nine months ended September 30,
(In thousands)	2021		2020		2021		2020
Net loss	$	(13,561)	$	(92,208)	$	(17,193)	$	(139,803)
Interest income		(893)		(16)		(1,739)		(238)
Interest expense		—		300		645		418
Change in fair value of warrant liabilities		(42,958)		—		(130,528)		—
Other expense, net		428		84		1,320		183
Provision for income taxes		(3)		12		72		32
Stock based compensation		10,734		2,382		38,769		7,727
Depreciation and amortization		505		311		1,420		904
CEO transition costs		—		—		5,398		—
Warranty liability policy change		—		—		(560)		—
Transaction bonus		—		—		1,653		—
Loss on purchase commitments		11,623		63,993		11,623		63,993
Inventory write-downs		582		2,570		582		2,570
Adjusted EBITDA	$	(33,543)	$	(22,572)	$	(88,538)	$	(64,214)

Description of Certain Components of Financial Data

Revenue

Revenue consists of revenue from the sale of products, such as medical devices and accessories, and related services, classified as subscription revenue on our condensed consolidated statements of operations and comprehensive loss, which are SaaS subscriptions and Support. SaaS subscriptions include licenses for teams and individuals as well as enterprise level subscriptions. For sales of products, which include the ultrasound devices and any ultrasound device accessories, revenue is recognized at a point in time upon transfer of control to the customer. SaaS subscriptions and Support are generally related to stand-ready obligations and are recognized ratably over time.

Over time as adoption of our devices increases through further market penetration and as practitioners in the Butterfly network continue to use our devices, we expect our annual revenue mix to shift more toward subscriptions. The quarterly revenue mix may be impacted by the timing of device sales.

From time to time, we may transition to higher prices for our product and services. The transition to higher prices may impact the timing and volume of sales and the related revenue. Partially as a result of a pricing adjustment in August 2021, we are seeing slowing sales in our ecommerce revenue channel.

Cost of revenue

Loss on product purchase commitments relates to inventory supply agreements where the expected losses exceed the benefit of the contracts. The Company considers a variety of factors and data points when determining the existence and scope of a loss for the minimum purchase commitment. The factors and data points include Company-specific forecasts which are reliant on the Company’s limited sales history, agreement-specific provisions, macroeconomic factors and market and industry trends. Determining the loss is subjective and requires significant management judgment and estimates. Future events may differ from those assumed in the Company’s assessment, and therefore the loss may change in the future.

Cost of product revenue consists of product costs including manufacturing costs, personnel costs and benefits, inbound freight, packaging, warranty replacement costs, payment processing fees and inventory obsolescence and write-offs. We expect our cost of product revenue to fluctuate over time due to the level of units fulfilled in any given period and decrease as a percentage of revenues over time as we focus on operational efficiencies in our supply chain. Our vendors may from time to time increase prices of certain inventory components that could in the future offset the operational efficiencies in our supply chain.

Table of Contents

Cost of subscription revenue consists of personnel costs, cloud hosting costs and payment processing fees. Because the costs and associated expenses to deliver our SaaS offerings are less than the costs and associated expenses of manufacturing and selling our device, we anticipate an improvement in profitability and margin expansion over time as our mix shifts increasingly towards subscriptions. We plan to continue to invest additional resources into our products to expand and further develop our offerings. The level and timing of investment in these areas could affect our cost of revenue in the future. We expect the cost of revenue to increase as a percentage of revenue in the near term due to the investments we are making, which will generally increase more rapidly than that of subscription revenue.

Research and development (R&D)

Research and development expenses primarily consist of personnel costs and benefits, facilities-related expenses, depreciation expense, consulting and professional fees, fabrication services, software and other outsourcing expenses. Most of our research and development expenses are related to developing new products and services and improving existing products and services, which we define as not having reached the point of commercialization, and improving our products and services that have been commercialized. Consulting expenses are related to general development activities and clinical/regulatory research. Fabrication services include certain third-party engineering costs, product testing and test boards. Research and development expenses are expensed as incurred. We expect to continue to make substantial investments in our product development, clinical and regulatory capabilities. Prospectively, we expect R&D spending to increase in absolute dollars in the near term and then fluctuate over time due to the level and timing of our product development efforts. R&D as a percentage of revenue will fluctuate given the level and timing of the product development efforts as well the amount of revenue recognized in a period.

Sales and marketing

Sales and marketing expenses primarily consist of personnel costs and benefits, third party logistics, fulfillment and outbound shipping costs, digital marketing, advertising, promotional, as well as conferences, meetings and other events and related facilities and information technology costs. We expect our sales and marketing expenses to increase in absolute dollars in the long term as we continue to increase the size of our direct sales force and sales support personnel and expand into new products and markets. We expect our sales and marketing expenses will also increase in the near term as we promote our brand through marketing and advertising initiatives, expand market presence and hire additional personnel to drive penetration and generate leads. We expect that sales and marketing expenses as a percentage of revenues will increase in the near term and then fluctuate over time as we evaluate expansion opportunities.

General and administrative

General and administrative expenses primarily consist of personnel costs and benefits, patent and filing fees, facilities costs and outside services. Outside services consist of professional services, legal and other professional fees. We expect our general and administrative expenses to increase in absolute dollars in the foreseeable future. We anticipate general and administrative expenses as a percentage of revenues will fluctuate over time due to the timing and amount of these expenses.

Results of Operations

We operate as a single reportable segment to reflect the way our chief operating decision maker (“CODM”) reviews and assesses the performance of the business. The accounting policies are described in Note 2 “Summary of Significant Accounting Policies” in our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

Table of Contents


	Three months ended September 30,								Nine months ended September 30,
	2021				2020				2021				2020
			% of				% of				% of				% of
(in thousands)	Dollars		revenue		Dollars		revenue		Dollars		revenue		Dollars		revenue
Revenue:
Product	$	10,848	74.2	%	$	8,621	85.1	%	$	33,455	76.8	%	$	25,820	84.4	%
Subscription		3,773	25.8	%		1,514	14.9	%		10,123	23.2	%		4,777	15.6	%
Total revenue:	$	14,621	100.0	%	$	10,135	100.0	%	$	43,578	100.0	%	$	30,597	100.0	%
Cost of revenue:
Loss on product purchase commitments		11,623	79.5	%		63,993	631.4	%		11,623	26.7	%		63,993	209.1	%
Product		7,584	51.9	%		14,619	144.2	%		21,090	48.4	%		35,266	115.3	%
Subscription		536	3.7	%		774	7.6	%		1,351	3.1	%		1,260	4.1	%
Total cost of revenue:	$	19,743	135.0	%	$	79,386	783.3	%	$	34,064	78.2	%	$	100,519	328.5	%
Gross profit	$	(5,122)	(35.0)	%	$	(69,251)	(683.3)	%	$	9,514	21.8	%	$	(69,922)	(228.5)	%

Operating expenses:
Research and development		21,654	148.1	%		11,971	118.1	%		54,459	125.0	%		36,427	119.1	%
Sales and marketing		14,203	97.1	%		5,538	54.6	%		34,550	79.3	%		17,408	56.9	%
General and administrative		16,008	109.5	%		5,068	50.0	%		67,928	155.9	%		15,651	51.2	%
Total operating expenses	$	51,865	354.7	%	$	22,577	222.8	%	$	156,937	360.1	%	$	69,486	227.1	%

Loss from operations	$	(56,987)	(389.8)	%	$	(91,828)	(906.0)	%	$	(147,423)	(338.3)	%	$	(139,408)	(455.6)	%
Interest income		893	6.1	%		16	0.2	%		1,739	4.0	%		238	0.8	%
Interest expense		—	—	%		(300)	(3.0)	%		(645)	(1.5)	%		(418)	(1.4)	%
Change in fair value of warrant liabilities		42,958	293.8	%		—	—	%		130,528	299.5	%		—	—	%
Other income (expense), net		(428)	(2.9)	%		(84)	(0.8)	%		(1,320)	(3.0)	%		(183)	(0.6)	%

Loss before provision for income taxes	$	(13,564)	(92.8)	%	$	(92,196)	(909.7)	%	$	(17,121)	(39.3)	%	$	(139,771)	(456.8)	%

Provision for income taxes		(3)	(0.0)	%		12	0.1	%		72	0.2	%		32	0.1	%

Net loss	$	(13,561)	(92.8)	%	$	(92,208)	(909.8)	%	$	(17,193)	(39.5)	%	$	(139,803)	(456.9)	%

Comparison of the three months ended September 30, 2021 and 2020

Revenue


	Three months ended September 30,
(in thousands)	2021		2020		Change		% Change
Revenue:
Product	$	10,848	$	8,621	$	2,227	25.8	%
Subscription		3,773		1,514		2,259	149.2	%
Total revenue:	$	14,621	$	10,135	$	4,486	44.3	%

Total revenue increased by $4.5 million, or 44.3%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020.

Product revenue increased by $2.2 million, or 25.8%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. The increase in product revenue was primarily driven by a higher volume of Butterfly iQ+ probes sold, as a result of our increased investment in our sales and marketing efforts domestically and internationally.

Table of Contents

Subscription revenue increased by $2.3 million, or 149.2%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. The increase was driven by an increased volume of our SaaS subscriptions sold in conjunction with sales of our devices as well as the increase from subscription renewals year over year.

Cost of revenue


	Three months ended September 30,
(in thousands)	2021			2020			Change		% Change
Cost of revenue:
Loss on product purchase commitments	$	11,623		$	63,993		$	(52,370)	(81.8)	%
Product		7,584			14,619			(7,035)	(48.1)	%
Subscription		536			774			(238)	(30.7)	%
Total cost of revenue	$	19,743		$	79,386		$	(59,643)	(75.1)	%
Percentage of revenue		135.0	%		783.3	%

Loss on product purchase commitments decreased by $52.4 million, or 81.8%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. The overall decrease is primarily due to a decrease in the purchase commitment loss related to a certain third-party vendor of $44.8 million. The decreased loss related to such vendor is due to the purchase commitment loss taken in the prior fiscal year as an estimate of future excess inventory and the additional purchase commitment loss recorded for the three months ended September 30, 2021. The additional loss was the result of changes to certain factors management considers when determining the existence and scope of a loss for the minimum purchase commitment. Additionally, the overall decrease is due to the non-recurrence of losses on other purchase commitments with other third-party vendors recorded in the prior year of $7.6 million.

Cost of product revenue decreased by $7.0 million, or 48.1%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. This decrease was driven by the sale of our second generation product, the Butterfly IQ+, which is less costly to produce, in the quarter ended September 30, 2021 as opposed to the Butterfly IQ in the quarter ended September 30, 2020. The overall decrease of product cost of revenue was primarily driven by decreases in product costs of $2.0 million and a decrease in net realizable value inventory adjustments and excess and obsolete inventory charges of $5.7 million. The decreases were partially offset by increases in component product costs related to global supply chain constraints of $0.5 million and other items that were not significant.

Cost of subscription revenue decreased by $0.2 million, or 30.7%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. This decrease was primarily driven by decreased payment processing fees partially offset by increased cloud hosting costs.

Research and development


	Three months ended September 30,
(in thousands)	2021			2020			Change		% Change
Research and development	$	21,654		$	11,971		$	9,683	80.9	%
Percentage of revenue		148.1	%		118.1	%

Research and development expenses increased by $9.7 million, or 80.9%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. This increase was primarily driven by increases in personnel costs including stock-based compensation expense of $7.9 million and an increase in professional service fees of $1.1 million as we continue to invest in expanding our overall product development capabilities and resources.

Sales and marketing


	Three months ended September 30,
(in thousands)	2021			2020			Change		% Change
Sales and marketing	$	14,203		$	5,538		$	8,665	156.5	%
Percentage of revenue		97.1	%		54.6	%

Table of Contents

Sales and marketing expenses increased by $8.7 million, or 156.5%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. This increase was primarily driven by increases in personnel costs including stock-based compensation of $5.5 million, an increase in demand generation costs of $1.3 million due to investments made to promote sales growth and an increase in travel, an increase in overhead costs of $0.6 million and entertainment costs of $0.7 million primarily related to the Company’s annual sales conference.

General and administrative


	Three months ended September 30,
(in thousands)	2021			2020			Change		% Change
General and administrative	$	16,008		$	5,068		$	10,940	215.9	%
Percentage of revenue		109.5	%		50.0	%

General and administrative expenses increased by $10.9 million, or 215.9%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. This increase was primarily driven by increases in personnel cost including stock-based compensation and benefits of $7.8 million associated with investments to scale up our back-office support and executive functions. In addition, the increase in general and administrative expenses is due to increased recruiting expense of $0.5 million to support our investments in personnel growth, increased professional service fees of $1.3 million and other general and administrative costs incremental to being a publicly traded company of $0.8 million.

Loss from operations


	Three months ended September 30,
(in thousands)	2021			2020			Change		% Change
Loss from operations	$	(56,987)		$	(91,828)		$	34,841	(37.9)	%
Percentage of revenue		(389.8)	%		(906.0)	%

Loss from operations decreased by $34.8 million, or 37.9%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. This decrease was primarily a result of an increase in gross profit of $64.1 million partially offset by increases in operating expenses of $29.3 million. The increase in gross profit was due to higher volume of sales, lower cost of product revenue and lower losses on product purchase commitments.

Net loss


	Three months ended September 30,
(in thousands)	2021			2020			Change		% Change
Net loss	$	(13,561)		$	(92,208)		$	78,647	(85.3)	%
Percentage of revenue		(92.8)	%		(909.8)	%

Net loss decreased by $78.6 million, or 85.3%, for the three months ended September 30, 2021 compared to the three months ended September 30, 2020. This decrease in the net loss was primarily a result of a decrease in the operating loss of $34.8 million and the gain for the change in the fair value of the warrant liabilities of $43.0 million. The warrant liabilities were recorded as part of the Business Combination and therefore did not exist in the prior year.

Comparison of the nine months ended September 30, 2021 and 2020

Revenue


	Nine months ended September 30,
(in thousands)	2021		2020		Change		% Change
Revenue:
Product	$	33,455	$	25,820	$	7,635	29.6	%
Subscription		10,123		4,777		5,346	111.9	%
Total revenue:	$	43,578	$	30,597	$	12,981	42.4	%

Table of Contents

Total revenue increased by $13.0 million, or 42.4%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020.

Product revenue increased by $7.6 million, or 29.6%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The increase in product revenue was primarily driven by a higher volume of Butterfly iQ+ probes sold, as a result of our increased investment in our sales and marketing efforts domestically and internationally. For the nine months ended September 30, 2020, revenue was positively impacted by COVID-19, as the Butterfly iQ was utilized in the monitoring of acute symptoms of COVID-19. We are unable to measure precisely the positive impact of COVID-19 on our revenue for the nine months ended September 30, 2020.

Subscription revenue increased by $5.3 million, or 111.9%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The increase was driven by an increased volume of our SaaS subscriptions sold in conjunction with sales of our devices as well as the increase from subscription renewals year over year.

Cost of revenue


	Nine months ended September 30,
(in thousands)	2021			2020			Change		% Change
Cost of revenue:
Loss on product purchase commitments	$	11,623		$	63,993		$	(52,370)	(81.8)	%
Product		21,090			35,266			(14,176)	(40.2)	%
Subscription		1,351			1,260			91	7.2	%
Total cost of revenue	$	34,064		$	100,519		$	(66,455)	(66.1)	%
Percentage of revenue		78.2	%		328.5	%

Loss on product purchase commitments decreased by $52.4 million, or 81.8%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The overall decrease is primarily due to a decrease in the purchase commitment loss related to a certain third-party vendor of $44.8 million. The decreased loss related to such vendor is due to the purchase commitment loss taken in the prior fiscal year as an estimate of future excess inventory and the additional purchase commitment loss recorded for the nine months ended September 30, 2021. The additional loss was the result of changes to certain factors management considers when determining the existence and scope of a loss for the minimum purchase commitment. Additionally, the overall decrease is due to the non-recurrence of losses on other purchase commitments with other third-party vendors recorded in the prior year of $7.6 million.

Cost of product revenue decreased by $14.2 million, or 40.2%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. This decrease was driven by the sale of our second generation product, the Butterfly IQ+, which is less costly to produce in the period ended September 30, 2021 as opposed to the Butterfly IQ in the period ended September 30, 2020. The overall decrease of product cost of revenue was primarily driven by decreases in product costs of $6.9 million, a decrease in warranty expense of $1.6 million and a decrease in net realizable value inventory adjustments and excess and obsolete inventory charges of $7.6 million. The decreases were partially offset by an increase in component product costs related to global supply chain constraints of $0.6 million, an increase in royalty fees due to increased sales of the Butterfly IQ+ of $0.6 million and an increase in payment processing fees of $0.6 million.

Cost of subscription revenue increased by $0.1 million, or 7.2%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. This increase was primarily driven by increased cloud hosting costs and amortization expense partially offset by decreased payment processing fees.

Research and development


	Nine months ended September 30,
(in thousands)	2021			2020			Change		% Change
Research and development	$	54,459		$	36,427		$	18,032	49.5	%
Percentage of revenue		125.0	%		119.1	%

Table of Contents

Research and development expenses increased by $18.0 million, or 49.5%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. This increase was primarily driven by increases in personnel costs including stock-based compensation expense of $16.3 million and an increase in professional service fees of $1.5 million as we continue to invest in expanding our overall product development capabilities and resources.

Sales and marketing


	Nine months ended September 30,
(in thousands)	2021			2020			Change		% Change
Sales and marketing	$	34,550		$	17,408		$	17,142	98.5	%
Percentage of revenue		79.3	%		56.9	%

Sales and marketing expenses increased by $17.1 million, or 98.5%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. This increase was primarily driven by an increase in personnel cost including stock-based compensation of $11.5 million, an increase in demand generation costs of $3.1 million due to investments made to promote sales growth, an increase in travel and entertainment costs of $0.7 million related to internal and external events and an increase in professional service fees of $0.8 million to support our sales and marketing efforts.

General and administrative


	Nine months ended September 30,
(in thousands)	2021			2020			Change		% Change
General and administrative	$	67,928		$	15,651		$	52,277	334.0	%
Percentage of revenue		155.9	%		51.2	%

General and administrative expenses increased by $52.3 million, or 334.0%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. This increase is primarily due to an increase in stock-based compensation expense of $23.2 million due to the additional awards granted and the performance condition for certain restricted stock units being achieved upon the Closing of the Business Combination. In addition to stock-based compensation, the increase was primarily driven by increased personnel costs of $13.7 million due to investments made to scale up our back-office support and executive functions, certain costs with regards to our CEO transition, an increase in recruiting expense of $3.5 million, an increase in professional services of $7.7 million and an increase in other general and administrative costs incremental to being a publicly traded company of $2.4 million.

Loss from operations


	Nine months ended September 30,
(in thousands)	2021			2020			Change		% Change
Loss from operations	$	(147,423)		$	(139,408)		$	(8,015)	5.7	%
Percentage of revenue		(338.3)	%		(455.6)	%

Loss from operations increased by $8.0 million, or 5.7%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. This increase was primarily a result of increases in operating expenses of $87.5 million partially offset by an increase in gross profit of $79.4 million. The increase in gross profit was primarily due to a higher volume of sales, lower cost of product revenue and lower losses on purchase commitments.

Net loss


	Nine months ended September 30,
(in thousands)	2021			2020			Change		% Change
Net loss	$	(17,193)		$	(139,803)		$	122,610	(87.7)	%
Percentage of revenue		(39.5)	%		(456.9)	%

Net loss decreased by $122.6 million, or 87.7%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. This decrease in net loss was primarily a result of the gain for the change in the fair

Table of Contents

value of the warrant liabilities of $130.5 million. The warrant liabilities were recorded as part of the Business Combination and therefore did not exist in the prior year. The gain was partially offset by the increased loss from operations of $8.0 million.

Liquidity and Capital Resources

Since our inception, our primary sources of liquidity are cash flows from operations and issuances of preferred stock and convertible notes. In addition, on February 12, 2021, we completed the Business Combination, and as a result we received gross proceeds of approximately $589 million. Our primary uses of liquidity are operating expenses, working capital requirements and capital expenditures. Cash flows from operations have been historically negative as we continue to develop new products and services and increase our sales and marketing efforts. We expect to be cash flow negative on an annual basis, although we may have quarterly results where cash flows from operations are positive.

We expect to continue to incur losses from operations, as we continue to invest in research and development of our products and in sales and marketing efforts into expanding new markets and verticals.

We expect that the funds raised in connection with the Business Combination and cash flows from operations will be sufficient to meet our liquidity, capital expenditure, and anticipated working capital requirements and fund our operations for at least the next 12 months. We expect to use the funds raised in connection with the Business Combination to scale our sales and marketing capabilities, develop new products and services and for working capital and general corporate purposes.

Our cash and cash equivalents and investments in marketable securities balance as of September 30, 2021 was $469.4 million. Our future capital requirements may vary from those currently planned and will depend on various factors, including our rate of revenue growth and the timing and extent of spending on strategic business initiatives.

The Company has restricted cash of $4.0 million as of September 30, 2021 to secure a letter of credit for one of the Company’s leases. The Company expects to maintain the letter of credit as security deposit for the duration of the lease.

Cash flows

Comparison of the period for the nine months ended September 30, 2021 and September 30, 2020

The following table summarizes our sources and uses of cash for the nine months ended September 30, 2021 and September 30, 2020:


	Nine months ended September 30,
(in thousands)	2021		2020
Net cash used in operating activities	$	(146,410)	$	(61,077)
Net cash used in investing activities		(319,769)		(2,597)
Net cash provided by financing activities		563,299		25,358
Net (decrease) increase in cash, cash equivalents and restricted cash	$	97,120	$	(38,316)

Net cash used in operating activities

Net cash used in operating activities represents the cash receipts and disbursements related to our activities other than investing and financing activities. We expect cash provided by historical financing activities such as the Business Combination will continue to be our primary source of funds to support operating needs and capital expenditures for the foreseeable future.

Net cash used in operating activities increased by $85.3 million, or 139.7%, for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The increase in net cash used in operating activities was due to a $86.4 million increase in accrued purchase commitments resulting from increased purchases of inventory components and purchase commitment losses recorded during the period. This increase was partially offset by a decrease of $13.9 million in inventories due to the costs of revenue recognized during the period. The increase in net cash used in

Table of Contents

operating activities was also due to an $8.6 million increase in prepaid expenses and other assets and a $10.6 million increase of vendor advances to be used in operations, as well as a $11.6 million increase in accounts payable and accrued expenses due to the timing of expenses and payments. Additionally, there was a $105.4 million increase in adjustments to reconcile net loss partially offset by a $122.6 million decrease in net losses.

Net cash used in investing activities

Net cash used in investing activities increased by $317.2 million for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The increase was primarily due to the investment activity for the funds received from the Business Combination.

Net cash provided by financing activities

For the nine months ended September 30, 2021, net cash provided by financing activities increased by $537.9 million compared to the nine months ended September 30, 2020. The increase was primarily due to net proceeds from the Business Combination of $547.8 million. Additionally, the proceeds from the exercise of stock options increased by $18.9 million which was partially offset by a $4.4 million loan repayment under the Paycheck Protection Program, the non-recurrence of $20.7 million of proceeds from the issuance of convertible debt in fiscal 2020 and $4.3 million of proceeds from the loan payable issued in fiscal 2020.

Contractual Obligations

As of September 30, 2021, our contractual obligations were as follows:


(in thousands)	Total		< 1 year		1-3 Years		3-5 Years		> 5 years
Operating leases	$	42,864	$	1,828	$	8,139	$	9,400	$	23,497
Purchase obligations (1)		129,467		59,576		69,891		—		—
Total contractual obligations	$	172,331	$	61,404	$	78,030	$	9,400	$	23,497

(1)

Purchase obligations include all legally binding contracts and relate to firm commitments for inventory purchases. Our purchase obligations are related to a contract for a key inventory component in our manufacturing process. Purchase orders that are not binding agreements are excluded from the table above.

Critical Accounting Policies and Significant Judgments and Estimates

Our management's discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about items that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

For our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, there have been no material changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in our Annual Report on Form 10-K.

Recently Adopted Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 “Summary of Significant Accounting Policies – Recent Accounting Pronouncements Adopted” to our condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q.

Table of Contents

Emerging Growth Company

We are an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Pursuant to the JOBS Act, an emerging growth company is provided the option to adopt new or revised accounting standards that may be issued by the FASB or the SEC either (i) within the same periods as those otherwise applicable to non-emerging growth companies or (ii) within the same time periods as private companies. We intend to take advantage of the exemption for complying with new or revised accounting standards within the same time periods as private companies. Accordingly, the information contained in this report may be different than the information you receive from other public companies.

We also intend to take advantage of some of the reduced regulatory and reporting requirements of emerging growth companies pursuant to the JOBS Act so long as we qualify as an emerging growth company, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding non-binding advisory votes on executive compensation and golden parachute payments.

However, based on the market value of the Company's common stock held by non-affiliates as of June 30, 2021, the Company expects to become a large-accelerated filer and thus cease to be an emerging growth company on December 31, 2021. At that time, the Company will be required to adopt new or revised accounting standards as required by public companies, including those standards which the Company had previously deferred pursuant to the JOBS Act. Additionally, the Company will no longer be able to take advantage of the reduced regulatory and reporting requirements of emerging growth companies described above.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

We did not have any floating rate debt as of September 30, 2021. Our cash, cash equivalents and marketable securities are comprised primarily of bank deposits, money market accounts and equity interests in mutual funds. The primary objective of our investments is the preservation of capital to fulfill liquidity needs. We do not enter into investments for trading or speculative purposes. Due to the short-term nature of these investments, we do not expect cash flows to be affected to any significant degree by a sudden change in market interest rates.

Foreign Exchange Risk

We operate our business primarily within the United States and currently execute the majority of our transactions in U.S. dollars. We have not utilized hedging strategies with respect to such foreign exchange exposure. This limited foreign currency translation risk is not expected to have a material impact on our condensed consolidated financial statements.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that, solely due to the Company’s material weakness as described below and in Amendment No. 1 to our Annual Report

Table of Contents

on Form 10-K/A for the year ended December 31, 2020 filed on May 12, 2021, our disclosure controls and procedures were not effective as of September 30, 2021.

Material Weakness in Internal Control over Financial Reporting

As previously disclosed in our Amendment No. 1 to our Annual Report on Form 10-K/A for the year ended December 31, 2020, we identified a material weakness in our internal controls over financial reporting related to inaccurate accounting for public warrants and private placement warrants issued in connection with our initial public offering. Notwithstanding this material weakness, management has concluded that our unaudited financial statements included in this Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with GAAP for each of the periods presented therein.

Plan for Remediation of the Material Weakness in Internal Control over Financial Reporting

In response to this material weakness, the Company’s management has expended, and will continue to expend, a substantial amount of effort and resources for the remediation and improvement of our internal control over financial reporting. While we have processes to properly identify and evaluate the appropriate accounting technical pronouncements and other literature for all significant or unusual transactions, we are improving these processes to ensure that the nuances of such transactions are effectively evaluated in the context of the increasingly complex accounting standards.

We are continually working to remediate the identified material weakness in internal control over financial reporting and execute on our plan to remediate the material weakness. Our plans at this time include acquiring enhanced access to accounting literature, research materials and documents and improving the communication among our personnel and third-party professionals with whom we may consult regarding the application of complex accounting transactions.

Our remediation plan can only be accomplished over time and will be continually reviewed to determine that it is achieving its objectives. We believe we are making progress toward achieving the effectiveness of our internal controls and disclosure controls; however we cannot provide any assurance that these remediation efforts will be successful or that our internal control over financial reporting will be effective as a result of these efforts.

Changes in Internal Control over Financial Reporting

Other than the changes made to remediate the material weakness described above, there were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Disclosure Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and implemented, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues within a company are detected. The inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

Table of Contents

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

We are not currently a party to any material legal proceedings.

Item 1A. Risk Factors

Our business, results of operations and financial condition are subject to various risks and uncertainties including the risk factors described under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, filed with the SEC on March 29, 2021, as amended on May 12, 2021 (the “2020 Annual Report on Form 10-K”). There have been no material changes to the risk factors described in the 2020 Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

Not applicable.

Issuer Purchases of Equity Securities

We did not repurchase any of our equity securities during the three months ended September 30, 2021.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

Item 6. Exhibits

See Exhibit Index.

Table of Contents

EXHIBIT INDEX


Exhibit Number	Exhibit Description	Filed Herewith	Incorporated by Reference herein from Form or Schedule	Filing Date	SEC File/ Reg. Number
10.1+	Employment Agreement, dated as of July 20, 2021, by and between Butterfly Network, Inc. and Todd M. Fruchterman, M.D., Ph.D.		Form 8-K (Exhibit 10.1)	7/22/2021	001-39292
10.2+	Offer of Employment Letter, dated as of August 12, 2021, by and between Butterfly Network, Inc. and Troy Quander.	X
10.3+	Executive Severance Plan, as amended.	X
10.4+	Separation Agreement, dated as of July 28, 2021, by and between Butterfly Network, Inc. and David Perri.		Form 10-Q (Exhibit 10.5)	8/9/2021	001-39292
10.5+	Amended and Restated Nonemployee Director Compensation Policy.		Form 8-K (Exhibit 10.1)	9/10/2021	001-39292
31.1	Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X
31.2	Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X
32*	Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X
101.INS	Inline XBRL Instance Document - The instance document does not appear	X

Table of Contents


Exhibit Number	Exhibit Description	Filed Herewith	Incorporated by Reference herein from Form or Schedule	Filing Date	SEC File/ Reg. Number
	in the Interactive Data File because its Inline XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document.	X
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.	X
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.	X
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.	X
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.	X
104	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)	X

+	Management contract or compensatory plan or arrangement.

The certifications attached as Exhibit 32 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Butterfly Network, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	BUTTERFLY NETWORK, INC.

Date: November 15, 2021	By:	/s/ Todd Fruchterman, M.D., Ph.D.
		Todd Fruchterman, M.D., Ph.D.
		President and Chief Executive Officer

Date: November 15, 2021	By:	/s/ Stephanie Fielding
		Stephanie Fielding
		Chief Financial Officer